◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 6978

Immunotech Biopharm Ltd (6978) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Immunotech Biopharm Ltd (6978) operates in the Biotechnology industry and is headquartered in Beijing, China with about 183 employees. Its market capitalization is roughly CNY 228 million. In the fiscal year ended 2025-12-31, 6978 reported CNY 0M in revenue and (CNY 231M) in net income.

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China.

Interactive charts & full statements →

6978 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 0MCNY 0MCNY 0MCNY 0M
Operating Income (EBIT)(CNY 156M)(CNY 169M)(CNY 224M)(CNY 269M)
Net Income(CNY 231M)(CNY 187M)(CNY 335M)(CNY 318M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6978 Free Cash Flow History

6978 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 603MCNY 564MCNY 846MCNY 879M
Total LiabilitiesCNY 620MCNY 580MCNY 675MCNY 373M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6978 viewer.

Other Companies in Biotechnology

← 6977All “0-9” companies6979 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.